Response to SARS-CoV-2 vaccination and antibodies persistence in multiple myeloma patients

Hematol Oncol. 2023 Feb;41(1):210-212. doi: 10.1002/hon.3051. Epub 2022 Aug 6.

Authors

Loredana Pettine¹, Marta Bortolotti², Bruno Fattizzo^{1

2}, Matteo C Da Vià^{1

2}, Dario Consonni³, Alessandra Pompa¹, Niccolò Bolli^{1

2}, Luca Baldini^{1

2}

Affiliations

¹ Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
² Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
³ Epidemiology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

No abstract available

Keywords: SARS-CoV-2; multiple myeloma; response to vaccination.

Publication types

Letter

MeSH terms

COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Multiple Myeloma* / therapy
SARS-CoV-2
Vaccination

Substances

COVID-19 Vaccines